Compare W W Grainger Inc (GWW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.41B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: W W Grainger Inc is far larger — about 12.8× Travere Therapeutics Inc. Common Stock's market cap, and W W Grainger Inc pays a 0.75% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GWW | TVTX | |
|---|---|---|
Market Cap | $62.41B | $4.88B |
Volume | 284,715 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $1.40K | $67.52 |
52-Week Low | $918.18 | $26.79 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $64.62B | $5.01B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.
Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
